You are missing some Flash content that should appear here! Perhaps your browser cannot display it, or maybe it did not initialise correctly.
Home › News & events

News & events

Latest press releases

Innate pharma reports higher annual revenue in 2011

February 7, 2012
  • Revenue of 11.7 million euros including payments from partners Bristol-Myers Squibb and Novo Nordisk A/S as well as research tax credit
  • Strong cash position with 46.6 million euros in cash, cash equivalents and current financial instruments as at December 31, 2011

    (IFRS unaudited provisional data)

 

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces revenue and other income of 11.7 million euros for the year 2011, compared to 4.3 million euros in 2010.

Novel immune regulation mechanism involving Natural Killer Cells described and published in "Science" magazine by a key academic partner of Innate Pharma

January 20, 2012
  • Innate Pharma co-owns intellectual property rights relating to the NKp46 receptor with INSERM, the French National Institute of Health and Medical Research
  • Endorses Innate Pharma’s fruitful collaboration with leading academics on Natural Killer cell science

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, is pleased to note today that an important discovery in the field of innate immunity, made by a team led by Professor Eric Vivier, Innate Pharma’s scientific co-founder at the Center of Immunology of Marseille-Luminy (CIML), has been published in the prestigious journal Science.

 

Half-year report on Innate Pharma's liquidity contract with Natixis Securities

January 2, 2012

Under the liquidity contract entrusted by INNATE PHARMA to NATIXIS SECURITIES, the following assets appeared on the liquidity account as at December 31, 2011:

  • 155,175 shares of INNATE PHARMA, and
  • 34,986.66 euros in cash.

Innate Pharma announces its financial calendar for 2012 as well as its participations to upcoming investor conferences

December 21, 2011

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces today its tentative financial calendar for 2012.

Innate Pharma SA announces its participation in Actionaria on November 18 & 19 in Paris

November 4, 2011

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces its participation in Actionaria, a forum dedicated to meeting with individual investors, on November 18 & 19, in Paris.

  • Innate Pharma will present the Company and answer your questions at its stand (A16, level 1).
  • Hervé Brailly, Chief Executive Officer, will be at the “Agora of Presidents” on Friday, November 18 at 11:25 am.

Innate Pharma announces its turnover for the first nine months of 2011 and updates on its cash position

November 4, 2011

Turnover of 3.1 million euros
Cash position as at September 30, 2011 of 49.3 million euros

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces a turnover of 3.1 million euros for the first nine months of 2011, compared with 0.2 million euros for the same period in 2010.

Innate Pharma to present at two upcoming investor conferences

September 14, 2011

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces that it will participate in the following investor conferences in the coming weeks:

  • Paris Midcap Event, Palais Brongniard, Paris, on September 22 & 23, 2011;
  • BIO Investor Forum, Palace Hotel, San Francisco, on October 25 & 26, 2011. During this event, Hervé Brailly, CEO of Innate Pharma, will participate in a panel on Cancer Immunotherapy (Immunotherapy: Heal Thyself, Tuesday, October 25th, 10:30am-11:25am, Twin Peaks N/S).

Financial results for the first half of 2011

August 31, 2011
  • Strong validation for Innate Pharma’s two most advanced programs
  • Controlled burn rate and strong cash position

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces today its financial results for the first half of 2011.

Half-year report on Innate Pharma's liquidity contract with Natixis Securities

July 18, 2011

Under the liquidity contract entrusted by Innate Pharma to Natixis Securities, the following assets appeared on the liquidity account as at June 30, 2011:

  •   121,882 shares of Innate Pharma, and
  •   33,311.37 euros in cash.

Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement for an Investigational Immuno-Oncology Biologic

July 6, 2011

(PRINCETON, New Jersey, and MARSEILLE, France, July 6, 2011) - Bristol-Myers Squibb Company (NYSE: BMY) and Innate Pharma S.A. (Euronext Paris: FR0010331421, IPH) today announced a global agreement for the development and commercialization of IPH2102, a novel antibody in Phase I development for the treatment of cancer.